(IGMS) – Analyst Ratings
-
RBC Capital Upgrades IGM Biosciences (IGMS) to Outperform, 'Pivoting Towards Becoming Key Player In Emerging Autoimmune Space'
-
BofA Securities Downgrades IGM Biosciences (IGMS) to Neutral
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to IGMS Stock Lookup